Macrovascular complications of diabetes in atherosclerosisprone mice

References

• American Heart Association. Heart disease and stroke statistics – 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115, e69–e171 (2007).
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA292, 2495–2499 (2004).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care2, 120–126 (1979).
   PubMedGoogle Scholar
• Lundberg V, Stegmayr B, Asplund K et al. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J. Intern. Med.241, 485–492 (1997).
   PubMed Web of Science ®Google Scholar
• Liao Y, Cooper RS, Ghali JK et al. Sex differences in the impact of coexistent diabetes on survival in patients with coronary heart disease. Diabetes Care16, 708–713 (1993).
   PubMed Web of Science ®Google Scholar
• Hu FB, Stampfer MJ, Solomon CG et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch. Intern. Med.161, 1717–1723 (2001).
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation115, 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Howard B, Smith S Jr et al. Prevention Conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation105(18), 2231–9 (2002).
   PubMed Web of Science ®Google Scholar
• Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res.100(10), 1415–1427 (2007).
   PubMed Web of Science ®Google Scholar
• Wu K, Huan Y. Diabetic atherosclerosis mouse models. Atherosclerosis191, 241–249 (2007).
   PubMed Web of Science ®Google Scholar
• Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest.97(7), 1767–1773 (1996).
   PubMed Web of Science ®Google Scholar
• Wang Z, Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes47(1), 50–56 (1998).
   PubMed Web of Science ®Google Scholar
• Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes43(11), 1326–1333 (1994).
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes57(9), 2461–2469 (2008).
   PubMed Web of Science ®Google Scholar
• Ihara Y, Egashira K, Nakano K et al. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J. Mol. Cell. Cardiol.43(4), 455–464 (2007).
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation106(22), 2827–2835 (2002).
   PubMed Web of Science ®Google Scholar
• Cipollone F, Iezzi A, Fazia M et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation108, 1070–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Reaven P, Merat S, Casanada F, Sutphin M, Palinski W. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol.17(10), 2250–6 (1997).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Isaacs A, Sehayek E, Breslow JL, Huang LS. Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis172(1), 47–53 (2004).
   PubMed Web of Science ®Google Scholar
• Berti JA, Salerno AG, Bighetti EJ, Casquero AC, Boschero AC, Oliveira HC. Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice. APMIS113(1), 37–44 (2005).
   PubMed Web of Science ®Google Scholar
• Wang J, Takeuchi T, Tanaka S et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dysfunction in the Mody mouse. J. Clin. Invest.103(1), 27–37 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes46(5), 887–894 (1997).
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in Type 1 diabetes. Nat. Rev. Endocrinol.5(4), 219–226 (2009).
   PubMed Web of Science ®Google Scholar
• Zipris D. Epidemiology of Type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin. Immunol.131(1), 11–23 (2009).
   PubMed Web of Science ®Google Scholar
• Keren P, George J, Keren G, Harats D. Non-obese diabetic (NOD) mice exhibit an increased cellular immune response to glycated-LDL but are resistant to high fat diet induced atherosclerosis. Atherosclerosis157(2), 285–292 (2001).
   PubMed Web of Science ®Google Scholar
• Renard CB, Kramer F, Johansson F et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest.114(5), 659–668 (2004).
   PubMed Web of Science ®Google Scholar
• Van Belle TL, Taylor P, von Herrath MG. Mouse models for Type 1 diabetes. Drug Discov. Today(2009) (In press).
   Google Scholar
• Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J. Pediatr.152(2), 165–170 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss R, Dziura J, Burgert T et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med.350, 2362–2374 (2004).
   PubMed Web of Science ®Google Scholar
• Hasty AH, Shimano H, Osuga J et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem.276(40), 37402–37408 (2001).
   PubMed Web of Science ®Google Scholar
• Wu KK, Wu TJ, Chin J et al. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis181(2), 251–259 (2005).
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
   PubMed Web of Science ®Google Scholar
• Gruen ML, Saraswathi V, Nuotio-Antar AM, Plummer MR, Coenen KR, Hasty AH. Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. Atherosclerosis186(1), 54–64 (2006).
   PubMed Web of Science ®Google Scholar
• Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am. J. Physiol. Endocrinol. Metab.282(1), E207–E214 (2002).
   PubMed Web of Science ®Google Scholar
• Huang ZH, Reardon CA, Mazzone T. Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes55(12), 3394–3402 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Navarro H, Vila-Caballer M, Pastor MF et al. Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice. Front. Biosci.12, 2291–2298 (2007).
   PubMed Web of Science ®Google Scholar
• González-Navarro H, Vinué A, Vila-Caballer M et al. Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. Arterioscler. Thromb. Vasc. Biol.28(12), 2187–2194 (2008).
   PubMed Web of Science ®Google Scholar
• Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab.7(2), 125–134 (2008).
   PubMed Web of Science ®Google Scholar
• Han S, Liang CP, Westerterp M et al. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J. Clin. Invest.119(4), 1029–1041 (2009).
   PubMed Web of Science ®Google Scholar
• Han S, Liang CP, DeVries-Seimon T et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab.3(4), 257–266 (2006).
   PubMed Web of Science ®Google Scholar
• Baumgartl J, Baudler S, Scherner M et al. Myeloid lineage cell-restricted insulin resistance protects apolipoprotein E- deficient mice against atherosclerosis. Cell Metab.3(4), 247–256 (2006).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes45(Suppl. 3), S27–S30 (1996).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Dansky HM. Diabetic vascular disease: an experimental objective. Arterioscler. Thromb. Vasc. Biol.26(8), 1693–1701 (2006).
   PubMed Web of Science ®Google Scholar
• Mooradian AD. Dyslipidemia in Type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab.5(3), 150–159 (2009).
   PubMedGoogle Scholar
• Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ. Res.100(6), 769–781 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ. Why does diabetes increase atherosclerosis? I don’t know! J. Clin. Invest.114(5), 613–615 (2004).
   PubMed Web of Science ®Google Scholar
• Yi X, Maeda N. α-lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Diabetes55(8), 2238–2244 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Hu Y, Noh HL et al. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes. Diabetes57(6), 1674–1682 (2008).
   PubMed Web of Science ®Google Scholar
• Calkin AC, Giunti S, Sheehy KJ et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia51(9), 1731–1740 (2008).
   PubMed Web of Science ®Google Scholar
• Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia49(4), 766–774 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou M, Xu H, Pan L, Wen J, Liao W, Chen K. Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice. Eur. J. Pharmacol.590(1–3), 297–302 (2008).
   PubMed Web of Science ®Google Scholar
• Hou CJ, Tsai CH, Su CH et al. Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction. J. Histochem. Cytochem.56(8), 745–752 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complications19(3), 178–181 (2005).
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med.320, 915–924 (1989).
   PubMed Web of Science ®Google Scholar
• Bursell SE, Clermont AC, Aiello LP et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with Type 1 diabetes. Diabetes Care22(8), 1245–1251 (1999).
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Hoogwerf B et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care25(11), 1919–1927 (2002).
   PubMed Web of Science ®Google Scholar
• Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. prevention with vitamin E administration. Atherosclerosis182(2), 259–265 (2005).
   PubMed Web of Science ®Google Scholar
• Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis10(2), 316–323 (1990).
   PubMedGoogle Scholar
• Sargeant LA, Wareham NJ, Bingham S et al. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer–Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care23, 726–732 (2000).
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH. Low plasma ascorbate levels in patients with Type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet. Med.11, 893–898 (1994).
   PubMed Web of Science ®Google Scholar
• Will JC, Ford ES, Bowman, BA. Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. Am. J. Clin. Nutr.70, 49–52 (1999).
   PubMed Web of Science ®Google Scholar
• Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic Acid. Circulation105(12), 1485–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary α-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation117(3), 421–428 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis P, Stefanovic N, Pete J et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation115(16), 2178–2187 (2007).
   PubMed Web of Science ®Google Scholar
• Chew P, Yuen DY, Koh P et al. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arterioscler. Thromb. Vasc. Biol.29(6), 823–830 (2009).
   PubMed Web of Science ®Google Scholar
• Vikramadithyan RK, Hu Y, Noh HL et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest.115(9), 2434–2443 (2005).
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med.11, E9 (2009).
   PubMed Web of Science ®Google Scholar
• Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation106(2), 246–253 (2002).
   PubMed Web of Science ®Google Scholar
• Candido R, Allen TJ, Lassila M et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation109(12), 1536–1542 (2004).
   PubMed Web of Science ®Google Scholar
• Zuccollo A, Shi C, Mastroianni R et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation112(19), 3001–8 (2005).
   PubMed Web of Science ®Google Scholar
• Lassila M, Allen TJ, Cao Z et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol.24(5), 935–942 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Statistics 2009. Gollogly L (Ed.). World Health Organization, Geneva, Switzerland (2009).
   Google Scholar
• Lloyd DJ, McCormick J, Helmering J et al. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab.294(3), E496–E505 (2008).
   Google Scholar
• Malloy SI, Altenburg MK, Knouff C, Lanningham-Foster L, Parks JS, Maeda N. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler. Thromb. Vasc. Biol.24(1), 91–97 (2004).
   PubMed Web of Science ®Google Scholar